Endometrial changes from short-term therapy with CDB-4124, a selective progesterone receptor modulator

Modern Pathology

Volumn 22, Issue 3, 2009, Pages 450-459

  Ioffe, Olga B ^a   Zaino, Richard J ^b   Mutter, George L ^c  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

CDB 4124; Endometrium; Histopathology; Progesterone receptor modulator

Indexed keywords

17ALPHA ACETOXY 11BETA (4 DIMETHYLAMINOPHENYL) 21 METHOXY 19 NORPREGNA 4,9 DIENE 3,20 DIONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENDOMETRIUM BIOPSY; FEMALE; HISTOLOGY; HUMAN; MENSTRUAL CYCLE; PRIORITY JOURNAL; WORLD HEALTH ORGANIZATION;

ADULT; ENDOMETRIOSIS; ENDOMETRIUM; FEMALE; HUMANS; LEIOMYOMA; NORPREGNADIENES; PREMENOPAUSE; RECEPTORS, PROGESTERONE; UTERINE NEOPLASMS;

EID: 61349195008     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2008.204     Document Type: Article

References (25)

1. Attardi BJ, Burgenson J, Hild SA, et al. In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone. J Steroid Biochem Mol Biol 2004;88:277-288.
2. Chwalisz K, Larsen L, Mattia-Goldberg C, et al. A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertil Steril 2007;87:1399-1412.
3. Demanno D, Elger W, Garg R, et al. Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy. Steroids 2003;68:1019-1032.
4. Fiscella K, Eisinger SH, Meldrum S, et al. Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstet Gynecol 2006;108:1381-1387.
5. Steinauer J, Pritts EA, Jackson R, et al. Systematic review of mifepristone for the treatment of uterine leiomyomata. Obstet Gynecol 2004;103:1331-1336.
6. Chabbert-Buffet N, Meduri G, Bouchard P, et al. Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Hum Reprod Update 2005;11:293-307.
7. Horne FM, Blithe D. Progesterone receptor modulators and the endometrium: changes and consequences. Hum Reprod Update 2007;13:567-580.
8. Noyes RW, Hertig AT, Rock J. Dating the endometrial biopsy. Am J Obstet Gynecol 1975;122:262-263.
9. Mutter GL, Zaino RJ, Baak JPA, et al. The benign endometrial hyperplasia sequence and endometrial intraepithelial neoplasia. Int J Gynecol Pathol 2007;26:103-114.
10. Williams AR, Critchley HO, Osei J, et al. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata. Hum Reprod 2007;22:1696-1704.
11. Baird DT, Brown A, Critchley HO, et al. Effect of long-term treatment with low-dose mifepristone on the endometrium. Hum Reprod 2003;18:61-68.
12. Mutter GL, Bergeron C, Deligdisch L, et al. The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod Path 2008;21:591-598.
13. Attardi BJ, Burgenson J, Hild SA, et al. CDB-4124 and its putative monodemethylated metabolite, CDB-4453, are potent antiprogestins with reduced antiglucocorticoid activity: in vitro comparison to mifepristone and CDB-2914. Mol Cell Endocrinol 2002;188: 111-123.
14. Silverberg SG, Mutter GL, Kurman RJ, et al. Tumors of the uterine corpus: epithelial tumors and related lesions In: Tavassoli FA, Stratton MR (eds). WHO Classification of Tumors: Pathology and Genetics of Tumors of the Breast and Female Genital Organs 1st edn IARC Press: Lyon, France, 2003, pp 221-232.
15. Dueholm M, Lundorf E, Olesen F. Imaging techniques for evaluation of the uterine cavity and endometrium in premenopausal patients before minimally invasive surgery. Obstet Gynecol Surv 2002;57:388-403.
16. Brenner RM, Slayden OD, Nayak NR, et al. A role for the androgen receptor in the endometrial antiproliferative effects of progesterone antagonists. Steroids 2003;68:1033-1039.
17. Narvekar N, Cameron S, Critchley HO, et al. Low-dose mifepristone inhibits endometrial proliferation and up-regulates androgen receptor. J Clin Endocrinol Metab 2004;89:2491-2497.
18. Slayden OD, Nayak NR, Burton KA, et al. Progesterone antagonists increase androgen receptor expression in the rhesus macaque and human endometrium. J Clin Endocrinol Metab 2001;86:2668-2679.
19. Chwalisz K, Brenner RM, Fuhrmann UU, et al. Antiproliferative effects of progesterone antagonists and progesterone receptor modulators on the endometrium. Steroids 2000;65:741-751.
20. Hickey M, Krikun G, Kodaman P, et al. Long-term progestin-only contraceptives result in reduced endometrial blood flow and oxidative stress. J Clin Endocrinol Metab 2006;91:3633-3638.
21. McGavigan CJ, Dockery P, Metaxa-Mariatou V, et al. Hormonally mediated disturbance of angiogenesis in the human endometrium after exposure to intrauterine levonorgestrel. Hum Reprod 2003;18:77-84.
22. Simbar M, Manconi F, Markham R, et al. A three-dimensional study of endometrial microvessels in women using the contraceptive subdermal levonorgestrel implant system, norplant. Micron 2004;35:589-595.
23. Narvekar N, Critchley HO, Cheng L, et al. Mifepristone-induced amenorrhoea is associated with an increase in microvessel density and glucocorticoid receptor and a decrease in stromal vascular endothelial growth factor. Hum Reprod 2006;21:2312-2318.
24. Eisinger SH, Bonfiglio T, Fiscella K, et al. Twelve-month safety and efficacy of low-dose mifepristone for uterine myomas. J Minim Invasive Gynecol 2005;12:227-233.
25. Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/ Progestin Interventions (PEPI) Trial. JAMA 1996;275:370-375.